Combating the Threat of Pandemic Influenza: Drug Discovery Approaches

Drug discovery for influenza antivirals Priorities for combating pandemic influenza include rapid detection and identification, the quick administration of available drugs to treat the infection, the development of new antivirals, and the development of vaccines. Since lead-time may be required to produce an effective vaccine, antivirals would serve as a key first line of defense in containing an outbreak. Diverse antivirals, acting through different mechanisms, would help stay the development of resistant viruses. Thus, drug discovery for influenza antivirals is an important public health-related endeavor. With chapters contributed by leading international specialists, this guide gets readers up to speed on the latest advances and technologies in diverse approaches to drug discovery, covering: * Existing antivirals, including broadly effective anti-respiratory virus agents * The development of high-throughput screening assays * IFN resistance * The development of nucleic acid-based antiviral drugs * Antiviral RNAi strategies targeting influenza virus * Other promising antiviral drug discovery strategies Combating the Threat of Pandemic Influenza: Drug Discovery Approaches consolidates the latest information on diverse approaches into one comprehensive resource. It is an invaluable, hands-on reference for researchers in medicinal chemistry, pharmaceutical chemistry, drug discovery, biochemistry, virology, microbiology, and public health.Content: Chapter 1 Existing Influenza Antivirals: Their Mechanisms of Action and Potential in the Face of Avian Influenza (pages 1–37): Erik De ClercqChapter 2 Development of High?Throughput Screening Assays for Influenza (pages 38–72): Diana L. Noah, E. Lucile White and James W. NoahChapter 3 Mechanisms of IFN Resistance by Influenza Virus (pages 73–97): Heather J. Ezelle and Bret A. HasselChapter 4 Broadly Effective Anti?Respiratory Virus Agents (pages 98–125): Shiro ShigetaChapter 5 Current Status on Development of Nucleic Acid?Based Antiviral Drugs Against Influenza Virus Infection (pages 126–147): Jonathan P. Wong, Mary E. Christopher, Murray Cairns, L.?Q. Sun, Roderic M. K. Dale and Andres M. SalazarChapter 6 Antiviral RNA Interference Strategies Targeting Influenza Virus and Other Respiratory Viruses (pages 148–165): Joost Haasnoot and Ben BerkhoutChapter 7 Promising Antiviral Glyco?Molecules from an Edible Alga (pages 166–182): Toshimitsu Hayashi, Kyoko Hayashi, Kenji Kanekiyo, Yuko Ohta, Jung?Bum Lee, Minoru Hashimoto and Takahisa NakanoChapter 8 Rational Design of an Anti?Adhesion Drug for Influenza (pages 183–208): Nicolai V. Bovin and Alexandra S. GambaryanChapter 9 Understanding Influenza Neuraminidase Inhibitors Using Quantitative Structure–Activity Relationship (QSAR) Models (pages 209–225): Rajeshwar P. Verma and Corwin HanschChapter 10 Peptide Inhibitors Targeting Virus?Cell Fusion in Class I Enveloped Viruses (pages 226–246): George F. GaoChapter 11 Novel Influenza Therapeutics (pages 247–264): Laura M. Aschenbrenner, Nicole Pelletier, Mang Yu and Fang Fang